{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[
    {
      "abstracts":[
        {
          "abstract":"Huang, Y. et al. Abstract# 128:1756, 2016",
          "link":"http://www.bloodjournal.org/content/128/22/1756?sso-checked=true"
        }
      ],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx3",
      "pmids":[],
      "tumorType":{
        "children":{},
        "code":"DLBCLNOS",
        "color":"LimeGreen",
        "id":490,
        "level":5,
        "mainType":{
          "id":null,
          "name":"Mature B-Cell Neoplasms",
          "tumorForm":"LIQUID"
        },
        "name":"Diffuse Large B-Cell Lymphoma, NOS",
        "parent":"MBN",
        "tissue":"Lymphoid",
        "tumorForm":"LIQUID"
      }
    },
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx3",
      "pmids":[
        "24362818",
        "25713363",
        "26366712"
      ],
      "tumorType":{
        "children":{},
        "code":"FL",
        "color":"LimeGreen",
        "id":286,
        "level":5,
        "mainType":{
          "id":null,
          "name":"Mature B-Cell Neoplasms",
          "tumorForm":"LIQUID"
        },
        "name":"Follicular Lymphoma",
        "parent":"MBN",
        "tissue":"Lymphoid",
        "tumorForm":"LIQUID"
      }
    }
  ],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"KMT2D, a tumor suppressor and histone methyltransferase, is one of the most frequently mutated genes in cancer.",
  "highestDiagnosticImplicationLevel":"LEVEL_Dx3",
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"02/16/2018",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "24633898",
        "24240169",
        "26366712"
      ]
    },
    "description":"Truncating mutations are the most common cancer-associated mutations of KMT2D and lead to several forms of C-terminally truncated proteins causing mRNA degradation and nonsense-mediated decay (PMID: 24633898). These alterations ablate the SET domain of KMT2D leading to global loss of methyltransferase activity and dysregulation of gene expression (PMID: 24240169). Conditional deletion of KMT2D in mice result in enhanced B cell proliferation and increases tumor development in a BCL2 overexpression model (PMID: 26366712).",
    "knownEffect":"Likely Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"G1235Vfs*95",
    "alterationType":null,
    "consequence":"frameshift_variant",
    "entrezGeneId":8085,
    "hgvs":"12:g.49049884del",
    "hugoSymbol":"KMT2D",
    "id":null,
    "proteinEnd":1235,
    "proteinStart":1235,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The KMT2D G1235Vfs*95 mutation is likely oncogenic.",
  "vus":false
}